Department of Infectious Diseases and Clinical Microbiology, Fırat University School of Medicine, Elazığ, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University School of Medicine, Hatay, Turkey.
Turk J Gastroenterol. 2021 Jul;32(7):581-585. doi: 10.5152/tjg.2020.19378.
BACKGROUND/AIMS: PTX-3 is an important marker that plays a role in suppressing inflammation and tissue repair. The aim of this study is to investigate the diagnostic and prognostic characteristics of PTX-3 in CHB patients and the relationship between PTX-3 levels and fibrosis.
A total of 52 CHB patients and 40 healthy subjects were included in the study. All of the CHB patients underwent liver biopsy and were then scored using a Ishak histologic scoring system. Blood samples were collected to evaluate the PTX-3 levels.
Of the subjects who participated in the study, 53% were female. PTX-3 levels were determined as 5.63ng/mL in the control group, and as 0.88ng/mL in the CHB patient group. PTX-3 levels were found to be 1.19ng/mL in stage 1, 0.89ng/mL in stage 2, 0.68ng/mL in stage 3 and 0.55ng/mL in stage 4. Of the CHB patients, 44.2% had significant fibrosis, while 55.7% were identified as not having significant fibrosis. PTX-3 values were 0.64 and 1.0ng/mL in patients with and without significant fibrosis, respectively. The cut-off value for PTX-3 in predicting the absence of significant fibrosis was estimated as 0.9ng/mL.
CHB patients were found to have lower serum PTX-3 levels compared to the control group, and these levels decreased even further as the fibrosis stage progressed in these patients. In addition, the significant decrease in PTX-3 levels in patients with stage 1 fibrosis compared to the control group shows that PTX-3 can be used as a non-invasive marker for the early detection of fibrosis (p<0.001).
背景/目的：PTX-3 是一种重要的标志物，可抑制炎症和组织修复。本研究旨在探讨 PTX-3 在 CHB 患者中的诊断和预后特征，以及 PTX-3 水平与纤维化之间的关系。
本研究共纳入 52 例 CHB 患者和 40 例健康对照者。所有 CHB 患者均行肝活检，并采用 Ishak 组织学评分系统进行评分。采集血样评估 PTX-3 水平。
在参与研究的受试者中，53%为女性。对照组 PTX-3 水平为 5.63ng/mL，CHB 患者组为 0.88ng/mL。1 期患者 PTX-3 水平为 1.19ng/mL，2 期为 0.89ng/mL，3 期为 0.68ng/mL，4 期为 0.55ng/mL。CHB 患者中，44.2%有显著纤维化，55.7%无显著纤维化。有显著纤维化的患者 PTX-3 值为 0.64ng/mL，无显著纤维化的患者为 1.0ng/mL。预测无显著纤维化的 PTX-3 截断值估计为 0.9ng/mL。
与对照组相比，CHB 患者血清 PTX-3 水平较低，且随着纤维化程度的进展，患者血清 PTX-3 水平进一步降低。此外，1 期纤维化患者 PTX-3 水平较对照组显著降低，表明 PTX-3 可作为纤维化早期检测的非侵入性标志物（p<0.001）。
